February 1978
Volume 17, Issue 2
Free
Articles  |   February 1978
Host response to allogeneic implants in the anterior chamber of the rat eye.
Investigative Ophthalmology & Visual Science February 1978, Vol.17, 140-148. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R L Vessella, S Raju, J V Cockrell, J B Grogan; Host response to allogeneic implants in the anterior chamber of the rat eye.. Invest. Ophthalmol. Vis. Sci. 1978;17(2):140-148.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

The anterior chamber of the eye has long been considered an immunologically privileged site, but the nature of this privilege has been re-examined recently. In our study, we used rats with defined genetic differences as the donors and the recipients. Implants were from split-ear sections, and the host response was measured both in vivo, by implant survival time, and in vitro, by the mixed-leukocyte reaction and the 51Cr-release cytotoxicity assay. Controls consisted of syngeneic implants and allogeneic orthotopic skin grafts. This study has shown that (1) host sensitization occurs approximately 7 days after implantation, (2) cytotoxic effector cells are produced by day 14, with a peak on day 21, (3) implant survival time is long in spite of the presence of competent effector cells, and (4) the survival time of implants is directly related to the degree of genetic histoincompatibility. The reasons for the long implant survival in hosts with a demonstrable immune reactivity has not been established, but the survival time appears to be related to the route of sensitization (vascular rather than lymphatic), which lends itself to the production of serum blocking factors and the procurement of supressor T cells.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×